Epicardial fat

A new cardiovascular therapeutic target

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume27
DOIs
StatePublished - Apr 1 2016

Fingerprint

Fats
Therapeutics
Pharmaceutical Preparations
Pharmacology
Dipeptidyl-Peptidase IV Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thiazolidinediones
Organ Specificity
Intra-Abdominal Fat
Metabolic Diseases
Transcriptome
Adipose Tissue
Drug Therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Epicardial fat : A new cardiovascular therapeutic target. / Iacobellis, Gianluca.

In: Current Opinion in Pharmacology, Vol. 27, 01.04.2016, p. 13-18.

Research output: Contribution to journalArticle

@article{76183842cee44ff09daa8c65379594b8,
title = "Epicardial fat: A new cardiovascular therapeutic target",
abstract = "Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.",
author = "Gianluca Iacobellis",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.coph.2016.01.004",
language = "English (US)",
volume = "27",
pages = "13--18",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Epicardial fat

T2 - A new cardiovascular therapeutic target

AU - Iacobellis, Gianluca

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.

AB - Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.

UR - http://www.scopus.com/inward/record.url?scp=84970917683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970917683&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2016.01.004

DO - 10.1016/j.coph.2016.01.004

M3 - Article

VL - 27

SP - 13

EP - 18

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -